Grafa News and Videos — Page 990

Alliance Resource Partners (NASDAQ:ARLP) reported its financial and operating results for the first quarter of 2026 on Monday, characterized by record-breaking performance in its royalty segments despite pricing challenges in the coal market.

SCHMID Group (NASDAQ:SHMD) released its first-quarter operational metrics for 2026 on Monday, reporting total revenues of €18.2 million.

Granite (NYSE:GVA) announced on Monday the completion of its acquisition of Kenny Seng Construction, a strategic move aimed at solidifying the company's vertically integrated construction and materials platform in Utah.

Eli Lilly (NYSE:LLY) has reached a definitive agreement to acquire Ajax Therapeutics, a biotechnology firm specializing in next-generation therapies for myeloproliferative neoplasms (MPNs).

The U.S. Food and Drug Administration has approved AstraZeneca’s (NASDAQ:AZN) Saphnelo (anifrolumab) for self-administration via a once-weekly autoinjector, the Saphnelo Pen.

Vertiv Holdings (NYSE:VRT) announced the acquisition of Strategic Thermal Labs (STL) on Monday, a move designed to deepen its engineering expertise in liquid cooling for high-density computing environments.

Easterly Government Properties (NYSE:DEA) reported its financial results for the first quarter of 2026 on Monday, highlighting a period of strategic acquisition and capital activity.

Adagio Medical Holdings (NASDAQ:ADGM) unveiled positive six-month results from its FULCRUM-VT clinical trial on Monday, providing the foundational data required for its forthcoming Food and Drug Administration (FDA) Premarket Approval application.

Domino’s Pizza (NASDAQ:DPZ) reported its first-quarter 2026 financial results on Monday, revealing a resilient bottom line supported by robust international expansion despite softening demand in several overseas markets.

Relay Therapeutics (NASDAQ:RLAY) announced on Monday that it will advance its lead candidate, zovegalisib, into a planned Phase 3 frontline trial for the treatment of PIK3CA-mutated, HR+/HER2- metastatic breast cancer.